Prognostic value of miR-221-3p, miR-342-3p and miR-491-5p expression in colon cancer

American Journal of Translational Research

Volumn 6, Issue 4, 2014, Pages 391-401

  Tao, Kun ^a,b   Yang, Jing ^a   Guo, Zhenhua ^a   Hu, Yuemei ^a   Sheng, Haihui ^c,d,e   Gao, Hengjun ^c,d,e   Yu, Hongyu ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c Institute of CMC Biobank and Translational Medicine   (China)

^d National Engineering Center for Biochip at Shanghai   (China)

^e TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Colon cancer; miR 221 3p; miR 342 3p; miR 491 5p; Prognosis

Indexed keywords

MICRORNA; MICRORNA 203 3P; MICRORNA 221 3P; MICRORNA 342 3P; MICRORNA 491 5P; MICRORNA 503 5P; MICRORNA 9 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE;

EID: 84904545100     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. He J and Chen W. 2012 Chinese Cancer Registry Annual Report. Military Medical Science Press 2012; 27-31.
3. Wan DS. Epidemiologic trend of and strategies for colorectal cancer. Chin J Cancer 2009; 28: 897-902.
4. Hegde SR, Sun W and Lynch JP. Systemic and targeted therapy for advanced colon cancer. Expert Rev Gastroenterol Hepatol 2008; 2: 135-149.
5. Kozomara A and Griffths-Jones S. miRBase: annotating high confdence microRNAs using deep sequencing data. Nucleic Acids Res 2014; 42: D68-D73.
6. Thomson DW, Bracken CP and Goodall GJ. Experimental strategies for microRNA target identifcation. Nucleic Acids Res 2011; 39: 6845-6853.
7. Munker R and Calin GA. MicroRNA profling in cancer. Clin Sci (Lond) 2011; 121: 141-158.
8. Wang H, Wu J, Meng X, Ying X, Zuo Y, Liu R, Pan Z, Kang T and Huang W. MicroRNA-342 inhibits colorectal cancer cell proliferation and invasion by directly targeting DNA methyltransfer-ase 1. Carcinogenesis 2011; 32: 1033-1042.
9. Nakano H, Miyazawa T, Kinoshita K, Yamada Y and Yoshida T. Functional screening identifes a microRNA, miR-491 that induces apoptosis by targeting Bcl-X(L) in colorectal cancer cells. Int J Cancer 2010; 127: 1072-1080.
10. Sarkar S, Dubaybo H, Ali S, Goncalves P, Kol-lepara SL, Sethi S, Philip PA and Li Y. Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN, p27(kip1), p57(kip2), and PUMA. Am J Cancer Res 2013; 3: 465-477.
11. Yu H, Gao G, Jiang L, Guo L, Lin M, Jiao X, Jia W and Huang J. Decreased expression of miR-218 is associated with poor prognosis in patients with colorectal cancer. Int J Clin Exp Pathol 2013; 6: 2904-2911.
12. Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH and Xu RH. Identification of miR-214 as a negative regulator of colorectal cancer liver metastasis via regulation of FGFR1 expression. Hepatology 2014; [Epub ahead of print].
13. Zhang JX, Song W, Chen ZH, Wei JH, Liao YJ, Lei J, Hu M, Chen GZ, Liao B, Lu J, Zhao HW, Chen W, He YL, Wang HY, Xie D and Luo JH. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol 2013; 14: 1295-1306.
14. Wu C, Cao Y, He Z, He J, Hu C, Duan H and Jiang J. Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer. Tohoku J Exp Med 2014; 232: 85-95.
15. Yu H, Duan B, Jiang L, Lin M, Sheng H, Huang J and Gao H. Serum miR-200c and clinical outcome of patients with advanced esophageal squamous cancer receiving platinum-based chemotherapy. Am J Transl Res 2013; 6: 71-77.
16. Wu C, Li M, Hu C and Duan H. Clinical signif-cance of serum miR-223, miR-25 and miR-375 in patients with esophageal squamous cell carcinoma. Mol Biol Rep 2014; 41: 1257-1266.
17. Xue Q, Sun K, Deng HJ, Lei ST, Dong JQ and Li GX. Anti-miRNA-221 sensitizes human colorec-tal carcinoma cells to radiation by upregulating PTEN. World J Gastroenterol 2013; 19: 9307-9317.
18. Wang X, Jiang F, Mu J, Ye X, Si L, Ning S, Li Z and Li Y. Arsenic trioxide attenuates the invasion potential of human liver cancer cells through the demethylation-activated microR-NA-491. Toxicol Lett 2014; 227: 75-83.
19. Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E, Cortes J, Iafrate AJ, Nuciforo P and Tabernero J. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann Oncol 2014; 25: 552-563.
20. Sun K, Wang W, Zeng JJ, Wu CT, Lei ST and Li GX. MicroRNA-221 inhibits CDKN1C/p57 expression in human colorectal carcinoma. Acta Pharmacol Sin 2011; 32: 375-384.
21. Qin J and Luo M. MicroRNA-221 promotes colorectal cancer cell invasion and metastasis by targeting RECK. FEBS Lett 2014; 588: 99-104.
22. Kneitz B, Krebs M, Kalogirou C, Schubert M, Joniau S, van Poppel H, Lerut E, Kneitz S, Scholz CJ, Strobel P, Gessler M, Riedmiller H and Spahn M. Survival in Patients with High-Risk Prostate Cancer Is Predicted by miR-221, Which Regulates Proliferation, Apoptosis, and Invasion of Prostate Cancer Cells by Inhibiting IRF2 and SOCS3. Cancer Res 2014; 74: 2591-2603.
23. Ye X, Bai W, Zhu H, Zhang X, Chen Y, Wang L, Yang A and Jia L. MiR-221 promotes trastu-zumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN. BMB Rep 2014; 47:268-73.
24. Di Martino MT, Gulla A, Cantafo ME, Lionetti M, Leone E, Amodio N, Guzzi PH, Foresta U, Conforti F, Cannataro M, Neri A, Giordano A, Tagliaferri P and Tassone P. In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget 2013; 4: 242-255.
25. Wang W, Sun K, Wu CT, Lei ST, Zeng JJ, Wu YJ and Li GX. Effect of miR-221-specifc inhibitor on the proliferation and apoptosis of human colorectal carcinoma cells. Nan Fang Yi Ke Da Xue Xue Bao 2011; 31: 674-677.
26. Yuan K, Xie K, Fox J, Zeng H, Gao H, Huang C and Wu M. Decreased levels of miR-224 and the passenger strand of miR-221 increase MBD2, suppressing maspin and promoting colorectal tumor growth and metastasis in mice. Gastroenterology 2013; 145: 853-864, e859.
27. Huang WC, Chan SH, Jang TH, Chang JW, Ko YC, Yen TC, Chiang SL, Chiang WF, Shieh TY, Liao CT, Juang JL, Wang HC, Cheng AJ, Lu YC and Wang LH. miRNA-491-5p and GIT1 serve as modulators and biomarkers for oral squa-mous cell carcinoma invasion and metastasis. Cancer Res 2014; 74: 751-764.
28. Guo R, Wang Y, Shi WY, Liu B, Hou SQ and Liu L. MicroRNA miR-491-5p targeting both TP53 and Bcl-XL induces cell apoptosis in SW1990 pancreatic cancer cells through mitochondria mediated pathway. Molecules 2012; 17: 14733-14747.
29. Li X, Liu Y, Granberg KJ, Wang Q, Moore LM, Ji P, Gumin J, Sulman EP, Calin GA, Haapasalo H, Nykter M, Shmulevich I, Fuller GN, Lang FF and Zhang W. Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma. Oncogene 2014; [Epub ahead of print].
30. Leivonen SK, Sahlberg KK, Makela R, Due EU, Kallioniemi O, Borresen-Dale AL and Perala M. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. Mol Oncol 2014; 8: 93-104.
31. Zhou Y, Li Y, Ye J, Jiang R, Yan H, Yang X, Liu Q and Zhang J. MicroRNA-491 is involved in metastasis of hepatocellular carcinoma by inhibitions of matrix metalloproteinase and epithelial to mesenchymal transition. Liver Int 2013; 33: 1271-1280.
32. Lujambio A and Lowe SW. The microcosmos of cancer. Nature 2012; 482: 347-355.
33. Chen Q, Si Q, Xiao S, Xie Q, Lin J, Wang C, Chen L, Chen Q and Wang L. Prognostic signifcance of serum miR-17-5p in lung cancer. Med Oncol 2013; 30: 353.
34. De Marchis ML, Ballarino M, Salvatori B, Puz-zolo MC, Bozzoni I and Fatica A. A new molecular network comprising PU.1, interferon regulatory factor proteins and miR-342 stimulates ATRA-mediated granulocytic differentiation of acute promyelocytic leukemia cells. Leukemia 2009; 23: 856-862.
35. Dacic S, Kelly L, Shuai Y and Nikiforova MN. miRNA expression profling of lung adenocarci-nomas: correlation with mutational status. Mod Pathol 2010; 23: 1577-1582.
36. Grady WM, Parkin RK, Mitchell PS, Lee JH, Kim YH, Tsuchiya KD, Washington MK, Paraskeva C, Willson JK, Kaz AM, Kroh EM, Allen A, Fritz BR, Markowitz SD and Tewari M. Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. On-cogene 2008; 27: 3880-3888.
37. Buffa FM, Camps C, Winchester L, Snell CE, Gee HE, Sheldon H, Taylor M, Harris AL and Ra-goussis J. microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res 2011; 71: 5635-5645.
38. Van der Auwera I, Limame R, van Dam P, Ver-meulen PB, Dirix LY and Van Laere SJ. Integrated miRNA and mRNA expression profling of the infammatory breast cancer subtype. Br J Cancer 2010; 103: 532-541.
39. Crippa E, Lusa L, De Cecco L, Marchesi E, Calin GA, Radice P, Manoukian S, Peissel B, Daidone MG, Gariboldi M and Pierotti MA. miR-342 regulates BRCA1 expression through modulation of ID4 in breast cancer. PLoS One 2014; 9: e87039.
40. Silva TD, Vidigal VM, Felipe AV, JM DEL, Neto RA, Saad SS and Forones NM. DNA methyla-tion as an epigenetic biomarker in colorectal cancer. Oncol Lett 2013; 6: 1687-1692.